|
Recently, infections caused by antibiotic-resistant bacteria continue to climb in the community and the hospital around the world. Our current antimicrobial agents are gradually becoming ineffective and a new pipeline of powerful compounds is needed urgently. A number of new antimicrobial compounds are in development, including novel glycopeptides (dalbavancin, telavancin, and oritavancin), daptomycin, tigecycline, ceftobiprole, iclaprim, and doripenem. The article will provide an update on the newly marketed and potentially effective antibacterial agents in the late-stage development pipeline. (Korean J Med 77:35-51, 2009) |
PDF Links
Full text via DOI
Download Citation
